<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431479</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006823</org_study_id>
    <secondary_id>NCI-2020-01242</secondary_id>
    <secondary_id>RG1006823</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>R01CA118953</secondary_id>
    <nct_id>NCT04431479</nct_id>
  </id_info>
  <brief_title>Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study</brief_title>
  <official_title>Predicting the Quality of Response to Specific Treatments (PQRST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial collects clinical data and blood samples to predict the quality of response to
      specific treatments in patients with chronic graft-versus-host disease (cGVHD) who are about
      to start initial or second-line therapy. Collecting and analyzing clinical data and blood
      samples from patients with cGVHD before and after treatment initiation may help doctors
      identify changes that may predict treatment response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

      Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and
      emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months
      after starting index treatment, and at start of a new systemic treatment. Patients also
      undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after
      starting index treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">August 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response according to the 2014 criteria</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>At the assessments, the 9 provider-reported National Institute of Health (NIH) organ severity scores (skin, eye, mouth, esophagus, upper gastrointestinal [GI], lower GI, liver, lung, and joint manifestations) will be collected reflecting disease activity in the past week. All scored items are single 4-7 point Likert scales. Based on past work, we anticipate it will take approximately 8 minutes to conduct the physical exam and record the relevant results. Pulmonary function testing results will be collected if available otherwise portable spirometry will be performed. Response will be assessed according to the recommendations of the 2014 NIH response measures publication or any applicable updates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to next systemic treatment</measure>
    <time_frame>From the start of the index medication until the addition of another systemic chronic graft versus host disease (cGVHD) treatment with death and treated recurrent malignancy considered competing events, assessed up to 3 years</time_frame>
    <description>Treated recurrent malignancy is defined as use of chemotherapy or targeted diseasespecific therapy, radiotherapy, therapeutic withdrawal of immunosuppression, donor lymphocyte infusion or second transplant for disease. Minimal residual disease or stable disease that does not require treatment is not considered a relapse. Patients lost to follow up are censored. Any addition of another systemic cGVHD treatment for medical reasons will be considered a failure, whether added because of a new or worsening manifestation of cGVHD, used as a &quot;steroidsparing agent,&quot; or substituted due to toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Duration of treatment is defined as the time until discontinuation of therapeutic systemic immunosuppression (adrenal replacement and topical/local therapies are allowed) without resumption for at least 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>From the start of the index medication to death with patients lost to follow up or alive at the conclusion of the study censored, assessed up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Non-relapse mortality is defined as death in remission, and relapse is considered a competing risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported outcomes</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be assessed using Lee symptom scale and Patient Reported Outcomes Measurement Information System (PROMIS). The summary score of the Lee Symptom Scale and the PROMIS Global will be calculated according to the instructions of the developers. For analyses assessing change in quality of life, improvement or worsening of the Summary symptom score by 6 points or more or the PROMIS Physical or Mental Functioning scales by 5 points or more compared to baseline will be considered a clinically significant change.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Observational (questionnaire, biospecimen, chart review)</arm_group_label>
    <description>Patients complete questionnaires over 10 minutes about physical symptoms, activity level, and emotional well-being and have their medical records reviewed at baseline, 1, 3, and 6 months after starting index treatment, and at start of a new systemic treatment. Patients also undergo collection of blood samples over 1-2 minutes at baseline and at 1 month after starting index treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood sample</description>
    <arm_group_label>Observational (questionnaire, biospecimen, chart review)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Review of medical chart</description>
    <arm_group_label>Observational (questionnaire, biospecimen, chart review)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (questionnaire, biospecimen, chart review)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Complete questionnaire</description>
    <arm_group_label>Observational (questionnaire, biospecimen, chart review)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic graft-versus-host disease (GVHD) who are starting first- or
        second-line therapy for GVHD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior allogeneic stem cell transplant, with any graft source, donor type, and GVHD
             prophylaxis

          -  No evidence of persistent or progressive malignancy at the time of enrollment

          -  Agrees to be evaluated at the transplant center before initial or second-line
             treatment is started (may be concurrent with the enrollment visit), and later between
             2-6 weeks, 3 months and 6 months after treatment is started or if a new therapy is
             started before 6 months

          -  Signed, informed consent

        Exclusion Criteria:

          -  Inability to comply with study procedures

          -  Uncontrolled psychiatric disorder

          -  Anticipated survival &lt; 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie J Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie J Lee</last_name>
    <phone>206-667-6190</phone>
    <email>sjlee@fredhutch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julianne Dunlap</last_name>
    <phone>206-667-4160</phone>
    <email>jdunlap@fredhutch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Pidala</last_name>
      <phone>888-663-3488</phone>
      <email>Joseph.Pidala@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Pidala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Harvard Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corey S. Cutler</last_name>
      <phone>617-632-5946</phone>
      <email>corey_cutler@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Corey S. Cutler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mukta Arora</last_name>
      <phone>612-624-0123</phone>
      <email>arora005@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Mukta Arora</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betty K. Hamilton</last_name>
      <phone>216-444-6833</phone>
      <email>HAMILTB2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Betty K. Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie L. Kitko</last_name>
      <phone>615-936-1762</phone>
      <email>carrie.l.kitko@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Carrie L. Kitko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie J. Lee</last_name>
      <phone>206-667-6190</phone>
      <email>sjlee@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Stephanie J. Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital/BC Cancer</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer White</last_name>
      <phone>604-875-4863</phone>
      <email>Jennifer.White1@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

